DNA vaccines for cancer too

Cancer Immunology, Immunotherapy

Volumn 55, Issue 2, 2006, Pages 119-130

  Yu, Min ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; COMPLEMENTARY DNA; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; NAKED DNA; VACCINIA VACCINE;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELLULAR IMMUNITY; COLONY FORMING UNIT GM; CPG ISLAND; DENDRITIC CELL; DNA MICROARRAY; DNA TRANSFECTION; ELECTROPORATION; EPSTEIN BARR VIRUS; GENE GUN; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT TRANSFORMATION; MEMORY CELL; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; VACCINIA VIRUS; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM; VIRUS TRANSFORMATION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, DNA;

EID: 28044436084     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0008-7     Document Type: Review

References (116)

1. Haupt K, Roggendorf M, Mann K (2002) The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) 227:227-237
2. Liu MA (1998) Vaccine developments. Nat Med 4:515-519
3. Lewis JD, Reilly BD, Bright RK (2003) Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 22:81-112
4. Sinkovics JG, Horvath JC (2000) Vaccination against human cancers (review). Int J Oncol 16:81-96
5. Yannelli JR, Wroblewski JM (2004) On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23:97-113
6. Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93:192-199
7. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29:121-125
8. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008
9. Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62:217-256
10. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN (1998) Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188:1075-1082
11. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B (1999) DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 189:169-178
12. Doe B, Selby M, Barnett S, Baenziger J, Walker CM (1996) Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A 93:8578-8583
13. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478
14. Corr M, Lee DJ, Carson DA, Tighe H (1996) Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555-1560
15. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA (1997) Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3:362-371
16. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC (2003) Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 112:109-117
17. Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, Wilson DM, Ayyavoo V, Weiner DB (2000) Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 18:974-979
18. Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL (2001) Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 19:543-547
19. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP (2000) Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51-55
20. Hauser H, Chen SY (2003) Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31:225-231
21. Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF (2004) Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53:825-834
22. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A (1992) Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1:363-369
23. Rock KL, Clark K (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721-3726
24. York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396
25. Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918-921
26. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R (2004) CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259-264
27. Amici A, Venanzi FM, Concetti A (1998) Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 47:183-190
28. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T (1999) T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 189:803-810
29. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL (1996) CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 70:1072-1079
30. Dyer CM, Zhan Y, Brady JL, Carbone FR, Smyth MJ, Lew AM (2004) Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after DNA immunization. Blood 103:3073-3075
31. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
32. Heath WR, Carbone FR (2001) Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1:126-134
33. Davis HL, Millan CL, Watkins SC (1997) Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther 4:181-188
34. Zhang L, Widera G, Bleecher S, Zaharoff DA, Mossop B, Rabussay D (2003) Accelerated immune response to DNA vaccines. DNA Cell Biol 22:815-822
35. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, Rabussay D, Lewis MG, Barnett S, Ulmer JB (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489-2493
36. Kaur R, Rauthan M, Vrati S (2004) Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. Vaccine 22:2776-2782
37. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3-15
38. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207
39. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515-1525
40. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Gaudernack G (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399-1400
41. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA (1993) A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53:3257-3261
42. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781-1787
43. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570-4577
44. Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Tezuka N, Sawai S, Inoue S, Fujino S, Maeda T, Itoh Y, Ogasawara K, Sato H, Ohkubo I, Kudo T (2002) Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 9:330-337
45. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993-11997
46. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY (2004) Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 111:86-95
47. Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313-1323
48. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89:293-300
49. Hodge JW (1996) Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 43:127-134
50. Zhou H, Luo Y, Mizutani M, Mizutani N, Becker JC, Primus FJ, Xiang R, Reisfeld RA (2004) A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 113:1792-1798
51. Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV (2005) A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF). Vaccine 23:1273-1283
52. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF (2002) Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8:2782-2787
53. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14:709-714
54. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249-293
55. Graham RA, Burchell JM, Taylor-Papadimitriou J (1996) The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 42:71-80
56. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688-694
57. Nawrath M, Pavlovic J, Moelling K (2001) Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J Mol Med 79:133-142
58. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ (2000) Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273-280
59. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN (1999) Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190:1717-1722
60. O I, Blaszczyk-Thurin M, Shen CT, Ertl HC (2003) A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther 10:678-688
61. Srinivasan R, Houghton AN, Wolchok JD (2002) Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun 2:8
62. Wolchok JD, Srinivasan R, Perales MA, Houghton AN, Bowne WB, Blachere NE (2001) Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. Cancer Immun 1:9
63. Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patino JA, Wolchok JD, Scheinberg DA, Houghton AN (2005) CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma. Clin Cancer Res 11:370-379
64. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845-5852
65. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK (1997) DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 159:1885-1892
66. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4:1281-1286
67. Forconi F, King CA, Sahota SS, Kennaway CK, Russell NH, Stevenson FK (2002) Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Immunology 107:39-45
68. Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK (2001) Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 19:760-764
69. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A (2002) Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87:989-1001
70. Hakim I, Levy S, Levy R (1996) A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 157:5503-5511
71. De Marco F, Hallez S, Brulet JM, Gesche F, Marzano P, Flamini S, Marcante ML, Venuti A (2003) DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res 23:1449-1454
72. Rocha-Zavaleta L, Alejandre JE, Garcia-Carranca A (2002) Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 66:86-95
73. Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI (2000) Immunotherapy of a human papilloma virus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 5:401-540
74. Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16:111-121
75. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM (2002) Encapsulated plasmid DNA treatment for human papilloma virus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8:1028-1037
76. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369-1375
77. Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC (2001) Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 8:128-138
78. Cheng L, Ziegelhoffer PR, Yang NS (1993) In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A 90:4455-4459
79. Tanigawa K, Yu H, Sun R, Nickoloff BJ, Chang AE (2000) Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother 48:635-643
80. Drabick JJ, Glasspool-Malone J, King A, Malone RW (2001) Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3:249-255
81. Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F (2001) Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 61:859-863
82. Hobson P, Barnfield C, Barnes A, Klavinskis LS (2003) Mucosal immunization with DNA vaccines. Methods 31:217-224
83. Klavinskis LS, Barnfield C, Gao L, Parker S (1999) Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162:254-262
84. Perrie Y, Frederik PM, Gregoriadis G (2001) Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19:3301-3310
85. Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, Greenberg HB, Herrmann JE (1998) Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72:5757-5761
86. Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5:387-391
87. Freimark BD, Blezinger HP, Florack VJ, Nordstrom JL, Long SD, Deshpande D.S, Nochumson S, Petrak KL (1998) Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 160:4580-4586
88. Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M, Plewe M, Liang X, Norman J, Smith A, Cheng SH (1996) A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A 93:11454-11459
89. Barnfield C, Brew R, Tilling R, Rae A, Wheeler C, Klavinskis LS (2000) The cellular basis of immune induction at mucosal surfaces by DNA vaccination. Dev Biol (Basel) 104:159-164
90. Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM (1991) Biodegradable microspheres as a vaccine delivery system. Mol Immunol 28:287-294
91. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Ilium L (2003) Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21:1478-1485
92. Toka FN, Pack CD, Rouse BT (2004) Molecular adjuvants for mucosal immunity. Immunol Rev 199:100-112
93. Klinman DM (2003) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2:305-315
94. Audibert F (2003) Adjuvants for vaccines a quest. Int Immunopharmacol 3:1187-1193
95. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98:9237-9242
96. Krieg AM (2004) Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6:88-95
97. More SH, Breloer M, von Bonin A (2001) Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. Int Immunol 13:1121-1127
98. Binder RJ, Han DK, Srivastava PK (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol 1:151-155
99. Li Z, Menoret A, Srivastava P (2002) Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14:45-51
100. Amigorena S (1998) Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res Immunol 149:661-662
101. Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, Reimann J (2002) Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol 168:108-117
102. Xiang Z, Ertl HC (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129-135
103. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P (1993) Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 91:566-576
104. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
105. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, Wu TC (2001) Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61:1080-1088
106. Sin JI, Kim J, Chattergoon M, Ayyavoo V, McCallus D, Ugen KE, Boyer JD, Weiner DB (2000) Engineering of DNA vaccines using molecular adjuvant plasmids. Dev Biol (Basel) 104:187-198
107. Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589-596
108. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA (1997) Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159:4999-5004
109. Dhiman N, Bonilla R, O'Kane DJ, Poland GA (2001) Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20:22-30
110. Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG (2000) Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 110:374-381
111. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561
112. Alizadeh AA, Staudt LM (2000) Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol 12:219-225
113. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3:56-63
114. Wang T, Hopkins DA, Fan L, Fanger G.R, Houghton R, Vedvick TS, Repasky E, Reed SG (2001) A p53 homologue and a novel serine proteinase inhibitor are over-expressed in lung squamous cell carcinoma. Lung Cancer 34:363-374
115. Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, Reed SG (2001) L552S, an alternatively spliced isoform of XAGE-1:is over-expressed in lung adenocarcinoma. Oncogene 20:7699-7709
116. Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG (2003) L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88:887-894